Rocket Posts $49.2M Q3 Loss, $279.4M Cash, Runway Into Q3 2028
RCKT is trading near its 52-week low of $2.165 (9.0% above the low).
Summary
Rocket reported a $49.2M third-quarter net loss and $279.4M in cash and investments, with runway guided into Q3 2028 after the PRV sale and first Hercules draw. Two things now drive the story: the Hercules covenants and the mid-2028 Danon topline.
Key Events · Earnings and Guidance · RCKT
-
Q3 Loss Narrowly Improves
Net loss of $49.2M versus $50.3M in Q3 2025. R&D fell $2.9M to $31.2M on lower headcount, while G&A rose $1.4M to $19.8M on post-marketing commitments.
-
Cash of $279.4M, Runway to Q3 2028
Cash, equivalents and investments totaled $279.4M at September 30, 2026, including the $180M PRV sale and the initial $35M Hercules draw. Management guides runway into Q3 2028, extendable into 2029 with further draws.
-
Hercules Covenants Tighten From July 2027
The $150M facility requires qualified cash of at least 55% of outstanding debt starting July 1, 2027, falling to 45% and 35% on the Tranche 2 and approval milestones but rising to 75% if the Danon program is terminated or fails. The covenant is waived while market cap is at least $600M.
-
Securities Suit Largely Dismissed
On October 28, 2026 the court dismissed with prejudice the claims over undisclosed Phase 2 safety events and trial design changes. The remaining dosing-progress claim and control-person claims were dismissed without prejudice.
Analysis · RCKT · Life Sciences
Operationally, the quarter was unremarkable: a $49.2M net loss versus $50.3M a year ago, with R&D down $2.9M on lower headcount. The balance sheet is what matters. Cash and investments of $279.4M, after the $180M PRV sale and the first $35M draw on the Hercules facility, fund operations into the third quarter of 2028, according to management. That removes near-term financing risk, but the Hercules terms carry a real string: from July 1, 2027 the company must hold qualified cash equal to 55% of outstanding debt, rising to 75% if the Danon program is halted or fails. Such a covenant could force a raise or a wind-down of spending precisely if the RP-A501 data disappoint. Also new: on October 28, 2026 the court dismissed with prejudice the core securities class action claims over the Phase 2 safety disclosures, leaving only a narrower dosing-progress claim alive.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RCKT was trading at $2.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $262.4M. The 52-week trading range was $2.17 to $5.45. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.